NCT02343042 2025-12-22
STOMP
Karyopharm Therapeutics Inc
Phase 1/2 Recruiting
Clinical Trials
12 trialsNCT04607772 2025-10-03
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Therapeutics Inc
Phase 1/2 Withdrawn
NCT02341014 2024-04-04
Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT02206425 2023-10-31
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
Oncotherapeutics
Phase 1/2 Completed
NCT02389543 2023-01-26
SLAM
Karyopharm Therapeutics Inc
Phase 1/2 Withdrawn
NCT02963610 2021-12-30
Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer
Fox Chase Cancer Center
Phase 1/2 Terminated
NCT00981708 2021-04-30
Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)
University of Athens
Phase 1/2 Completed
NCT01788189 2020-02-26
LeMLAR
University Hospital, Essen
Phase 1/2 Completed
NCT02075021 2018-10-15
rev/abraxane
NYU Langone Health
Phase 1/2 Terminated
NCT02983097 2018-01-19
R²-DHAP
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Phase 1/2 Terminated
NCT01010243 2012-05-30
MM03
University of Regensburg
Phase 1/2 Unknown
NCT00306813 2009-08-04
Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma
University of Wuerzburg
Phase 1/2 Completed